Difference between revisions of "Team:New York City/Integrated Practices"

 
(3 intermediate revisions by 2 users not shown)
Line 1: Line 1:
 
{{New_York_City}}
 
{{New_York_City}}
 
<html lang="en">
 
<html lang="en">
<head>
+
<head><style>
    <link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.1.3/css/bootstrap.min.css" integrity="sha384-MCw98/SFnGE8fJT3GXwEOngsV7Zt27NXFoaoApmYm81iuXoPkFOJwJ8ERdknLPMO" crossorigin="anonymous">
+
.social{
    <link rel="stylesheet" href="https://use.fontawesome.com/releases/v5.3.1/css/brands.css" integrity="sha384-rf1bqOAj3+pw6NqYrtaE1/4Se2NBwkIfeYbsFdtiR6TQz0acWiwJbv1IM/Nt/ite" crossorigin="anonymous">
+
            max-width: 50px;
    <link rel="stylesheet" href="https://use.fontawesome.com/releases/v5.3.1/css/fontawesome.css" integrity="sha384-1rquJLNOM3ijoueaaeS5m+McXPJCGdr5HcA03/VHXxcp2kX2sUrQDmFc3jR5i/C7" crossorigin="anonymous">
+
            max-height: auto;
    <style>
+
        }
 
         .container {
 
         .container {
 
             align-items: center;
 
             align-items: center;
Line 41: Line 41:
 
                                 <a class="dropdown-item" href="https://2018.igem.org/Team:New_York_City/Description">Description</a>
 
                                 <a class="dropdown-item" href="https://2018.igem.org/Team:New_York_City/Description">Description</a>
 
                                 <a class="dropdown-item" href="https://2018.igem.org/Team:New_York_City/Design">Design</a>
 
                                 <a class="dropdown-item" href="https://2018.igem.org/Team:New_York_City/Design">Design</a>
 +
                                <a class="dropdown-item" href="https://2018.igem.org/Team:New_York_City/Model">Model</a>
 +
                                <a class="dropdown-item" href="https://2018.igem.org/Team:New_York_City/InterLab">InterLab</a>
 
                             </div>
 
                             </div>
 
                         </li>
 
                         </li>
Line 49: Line 51:
 
                             </a>
 
                             </a>
 
                             <div class="dropdown-menu" aria-labelledby="navbarNB">
 
                             <div class="dropdown-menu" aria-labelledby="navbarNB">
                                 <a class="dropdown-item" href="https://2018.igem.org/Team:New_York_City/InterLab">InterLab</a>
+
                                 <a class="dropdown-item" href="https://2018.igem.org/Team:New_York_City/Notebook">Notebook</a>
 
                             </div>
 
                             </div>
 
                         </li>
 
                         </li>
Line 62: Line 64:
 
                                 <a class="dropdown-item" href="https://2018.igem.org/Team:New_York_City/Integrated_Practices">Integrated
 
                                 <a class="dropdown-item" href="https://2018.igem.org/Team:New_York_City/Integrated_Practices">Integrated
 
                                     Practices</a>
 
                                     Practices</a>
 +
                                <a class="dropdown-item" href="https://2018.igem.org/Team:New_York_City/Public_Engagement">Public
 +
                                    Engagement</a>
 
                                 <a class="dropdown-item" href="https://2018.igem.org/Team:New_York_City/Collaborations">Collaborations</a>
 
                                 <a class="dropdown-item" href="https://2018.igem.org/Team:New_York_City/Collaborations">Collaborations</a>
 
                             </div>
 
                             </div>
Line 86: Line 90:
  
 
<div class="container">
 
<div class="container">
     <p class="lead">Huntington's disease (HD) is a rare and deadly inherited disease, so our team was motivated to
+
     <p class="lead">Last year, our team focused on developing a modified RNA protein replacement technology for treating Huntington’s Disease. We were motivated to delve further into research at the RNA level after collaborating with the Huntington’s Disease Society of America. Through our collaboration, we realized that current research in Huntington’s Disease was not selective in specifically targeting mutated Huntingtin RNA strands. Instead of targeting mutated strands only, research would try to target both endogenous and mutated strands, thereby stopping all production of the Huntingtin protein and resulting in undesired side effects. To resolve this, our team began developing modified RNA technology that would specifically target mutated Huntingtin mRNA strands through a specific toehold recognition and exchange process, allowing the mutated strands to be replaced by a corrected synthetic mRNA strand. This year our team is taking this research further by testing the efficacy of the modified RNA replacement technology in Huntingtin cell lines to determine whether our treatment decreases the levels of mutated Huntingtin protein.
        develop a cure that would attack the root of the problem instead of solely relieving the symptoms. The
+
</p>
        severity of the symptoms, along with the late onset of the disease, affects victims both mentally and
+
        physically. Thus, we wanted to spread awareness of HD and our research to both the public and scientific
+
        community. We held information sessions within our respective high schools to educate students on HD as
+
        well as our ongoing research. We also visited organizations like the HDSA (Huntington's Disease Society of
+
        America) to present our project and discuss other ongoing research on HD such as Zinc Fingers. Most importantly,
+
        we had a rare opportunity to attend an Education Day event at HDSA Center of Excellence at Columbia
+
        University Medical Center and NYS Psychiatric Institute where we met Huntington's disease patients,
+
        their caregivers and advocates. Through direct outreach to institutions and educational communities
+
        such as our schools, the colleges/universities in our city, and affiliated organizations, we hoped to
+
        inspire further experimentation and interest in HD.</p>
+
 
</div>
 
</div>
 
<br/>
 
<br/>
 
<div class="container" align="center">
 
<div class="container" align="center">
    <div class="row" align="center">
+
        <div class="row" align="center">
        <div class="col-sm-3">
+
            <div class="col-sm-3">
 +
            </div>
 +
            <div class="col-sm-2">
 +
                <a href="https://www.facebook.com/HDResolution/"><img class="social" src="https://static.igem.org/mediawiki/2018/6/61/T--New_York_City--fb.png"></a>
 +
            </div>
 +
            <div class="col-sm-2">
 +
                <a href="https://twitter.com/HDNYC_iGEM"><img class="social" src="https://static.igem.org/mediawiki/2018/4/46/T--New_York_City--twit.png"></a>
 +
            </div>
 +
            <div class="col-sm-2">
 +
                <a href="https://www.instagram.com/nyc_igem/"><img class="social" src="https://static.igem.org/mediawiki/2018/0/0a/T--New_York_City--ig.png"></a>
 +
            </div>
 +
            <div class="col-sm-3">
 +
            </div>
 
         </div>
 
         </div>
        <div class="col-sm-2">
 
            <a href="https://www.facebook.com/HDResolution/"><i class="fab fa-facebook-f display-4"></i></a>
 
        </div>
 
        <div class="col-sm-2">
 
            <a href="https://twitter.com/HDNYC_iGEM"><i class="fab fa-twitter display-4"></i></a>
 
        </div>
 
        <div class="col-sm-2">
 
            <a href="https://www.instagram.com/nyc_igem/"><i class="fab fa-instagram display-4"></i></a>
 
        </div>
 
        <div class="col-sm-3">
 
        </div>
 
    </div>
 
    <br/>
 
</div>
 
<script src="https://code.jquery.com/jquery-3.3.1.slim.min.js" integrity="sha384-q8i/X+965DzO0rT7abK41JStQIAqVgRVzpbzo5smXKp4YfRvH+8abtTE1Pi6jizo" crossorigin="anonymous"></script>
 
<script src="https://cdnjs.cloudflare.com/ajax/libs/popper.js/1.14.3/umd/popper.min.js" integrity="sha384-ZMP7rVo3mIykV+2+9J3UJ46jBk0WLaUAdn689aCwoqbBJiSnjAK/l8WvCWPIPm49" crossorigin="anonymous"></script>
 
<script src="https://stackpath.bootstrapcdn.com/bootstrap/4.1.3/js/bootstrap.min.js" integrity="sha384-ChfqqxuZUCnJSK3+MXmPNIyE6ZbWh2IMqE241rYiqJxyMiZ6OW/JmZQ5stwEULTy" crossorigin="anonymous"></script>
 
 
</body>
 
</body>
 
</html>
 
</html>

Latest revision as of 01:39, 17 October 2018

Integrated Practices

Last year, our team focused on developing a modified RNA protein replacement technology for treating Huntington’s Disease. We were motivated to delve further into research at the RNA level after collaborating with the Huntington’s Disease Society of America. Through our collaboration, we realized that current research in Huntington’s Disease was not selective in specifically targeting mutated Huntingtin RNA strands. Instead of targeting mutated strands only, research would try to target both endogenous and mutated strands, thereby stopping all production of the Huntingtin protein and resulting in undesired side effects. To resolve this, our team began developing modified RNA technology that would specifically target mutated Huntingtin mRNA strands through a specific toehold recognition and exchange process, allowing the mutated strands to be replaced by a corrected synthetic mRNA strand. This year our team is taking this research further by testing the efficacy of the modified RNA replacement technology in Huntingtin cell lines to determine whether our treatment decreases the levels of mutated Huntingtin protein.